IMPORTANCE Hospital readmissions are common among patients receiving multiple medications, with considerable costs to the patients and society.
A pproximately 5% of all hospital admissions are thought to be attributable to adverse drug reactions.
1,2 Patients taking multiple drugs are at increased risk of drug-related problems, and medication errors, such as subtherapeutic treatment, overdosing, and adverse events, are all potential causes of hospital admission. [3] [4] [5] On average, 45% of all adverse drug reactions that lead to hospitalizations are preventable. 6 The transition from a hospital to a primary care setting is of particular concern because it is vulnerable to errors related to the communication of patients' medical treatment. [7] [8] [9] [10] [11] [12] Pharmacist-led medication reviews have been proposed as a solution to some of these problems. 13 Ample evidence suggests that pharmacist medication reconciliation or a discharge medication report can reduce the number of medication errors after discharge. [14] [15] [16] [17] [18] [19] The evidence regarding the clinical consequences of the reduced number of medication errors, however, is equivocal. Most of these studies had fairly simple single-component interventions and were thereby not likely to be successful in terms of preventing hard clinical outcomes. 20 Accordingly, a recent meta-analysis 21 found no clear evidence of fewer hospital admissions or deaths after medication review, but a reduced number of emergency contacts seemed plausible. Only 10 studies were included in the meta-analysis, and most of those were small or had short follow-up. The investigators concluded that high-quality trials with long-term follow-up are warranted to provide definitive evidence for the effect of medication reviews. 21 The aim of our large randomized clinical trial was to determine whether an in-hospital multifaceted pharmacist intervention based on medication review, motivational interview, and follow-up with the patient and the ongoing primary care physician (PCP) can reduce the rate of readmissions.
Methods

Trial Design and Patients
The randomized clinical multicenter Odense Pharmacist Trial Investigating Medication Interventions at Sector Transfer (OPTIMIST) was conducted among patients at the following 4 different acute admission wards in Denmark: Regional Hospital Viborg, Viborg; Holbaek Hospital, Holbaek; and Odense University Hospital, Odense and Svendborg. A copy of the full study protocol is available in the Supplement. The protocol was approved by the Danish Data Protection Agency. The National Committee on Health Research Ethics found that the study did not require ethical approval according to Danish law. Each patient provided written informed consent.
Patients were eligible if they were 18 years or older, had polypharmacy, 22 defined as use of 5 or more prescribed drugs on a daily basis, spoke and understood Danish, and were new acute admissions. Patients were excluded if they had been included in a similar study, were declared terminally ill, were suicidal, were in custody, were under isolation precautions, or had aphasia or severe dementia. Patients were enrolled from September 1, 2013, through April 23, 2015, and followed up for 6 months (final follow-up was completed on October 31, 2015) .
Pharmacist Intervention
Patients were randomized 1:1:1 to a usual care, a basic intervention, or an extended intervention group. Those randomized to usual care received no intervention beyond standard care.
In the basic intervention group, a structured, patientcentered medication review 23 was conducted by a clinical pharmacist once shortly after the patient was admitted, when laboratory data were available and the primary medical admission note was written. The following 3 questions were considered during medication review: Were any diagnoses untreated? Was the goal of treatment reached? Was the treatment in agreement with current national guidelines regarding dose, choice of drug, and time of treatment? We focused on the drugs most commonly implicated in admissions, such as low-dose aspirin, diuretics, anticoagulants, and nonsteroidal antiinflammatory drugs other than aspirin. 24 Furthermore, all drugs on the medication list were assessed by the indication for treatment, drug dose (considering renal failure, age, etc), adverse drug events, therapeutic duplication, dosage time and interval, drug formulation and strength, interactions, contraindications, precautions, and specific patient characteristics. If drugs were deemed unnecessary, the treatment was proposed to be discontinued. Our participating pharmacists were not authorized to implement changes in the patients' medication after having performed the medication review but documented proposed changes in the electronic patient record and, if possible, communicated with the physician in charge of the patient, who would then follow or reject the advice. In the extended intervention group, a similar medication review was conducted. In the basic and the extended intervention groups, the time spent on the medication review was a mean (SD) of 26.0 (14.7) minutes. In addition, on discharge of the patient, a medication reconciliation 25, 26 was conducted. The pharmacist used a 30-minute structured patient interview with a motivational interview approach, [27] [28] [29] including a comprehensive summary of changes in the drug therapy during the hospitalization. The interview included information of changed dose, new medicines, drug discontinuation, drug administration, adverse drug events, adherence, and cost. Motivational interviewing is a coaching method aimed at ensuring adequate patient behavior to prevent healthrelated events such as adverse drug reactions and other drugrelated problems.
For patients receiving the extended intervention, any drugrelated problem not dealt with during hospitalization was mailed or faxed after discharge to the individual patient's PCP. In addition to this process, a summary note containing information of changes in dose, new medicines, and drug therapy discontinuations was sent to the PCP and, if relevant, the nursing home. The PCP, caregiver, and primary care pharmacy were contacted by telephone (approximately 3 workdays after discharge). Follow-up calls with the PCP and nursing home or caregiver were conducted when any change in medication was made during the index hospitalization. The primary pharmacy was called when the clinical pharmacist from the hospital found it necessary, for example, to delete old prescriptions or address problems concerning dose-dispensed medication.
The interview in the follow-up telephone call was also based on principles of motivational interview and was routinely performed twice. The first interview was conducted 1 week after discharge, whereas a second interview was performed 6 months after discharge. If required, additional followups could be arranged. The mean (SD) total pharmacist time spent on all elements in the extended intervention was 114.0 (51.8) minutes.
All interventions were performed by trained clinical pharmacists. During the study, 13 different pharmacists, including 6 of us (L.V.R.
N., J.P.H., and C.S.E.), were involved in the data collection but not at the same time because of job change, maternity leave, etc. At most times, 2 study pharmacists participated at the same time per hospital. Furthermore, all pharmacists were trained in medication review workshops and had completed a 3-day course in motivational interviewing and subsequent practice sessions before entering the study.
Outcomes
The primary outcomes were the occurrence of readmission within 30 and 180 days and the occurrence of a prespecified composite end point of readmissions and emergency department (ED) visits within 180 days. The secondary outcomes were drug-related readmissions within 30 and 180 days after inclusion and all-cause and drug-related mortality.
The Danish health care system is almost fully tax funded, has universal coverage of citizens, and is based on the principles of free and equal access to health care for all citizens. 30 This process entails an almost universal registry coverage of health care contacts. Information about readmissions, ED visits, and deaths were drawn from the National Patient Register. 31 To evaluate whether a readmission or death should be classified as drug related, an adverse drug reaction or a doserelated therapeutic failure 32 had to be present. For this determination, all readmissions and deaths were manually reviewed by clinical pharmacists who were blinded to study allocation. The pharmacists reviewed all notes from the first 2 days of each readmission plus the discharge summary. If the case was unresolved based on these notes, additional notes were read. Laboratory data could be included in the assessment if necessary. Using a modified version of the Hallas criteria 32 and the World Health Organization criteria, 33 the pharmacist evaluated whether (1) the readmission was potentially drug induced and (2) a possible causal relationship existed All cases classified as a possible or stronger causal relationship were evaluated by a clinical pharmacologist (blinded to study allocation). The clinical pharmacologist would then evaluate the cases using the same method and decide whether the outcome was drug related. For drug-related mortality, only in-hospital deaths were assessed with respect to causality (ie, drug related or not). Deaths outside the hospital were included as outcomes but did not undergo causality assessment because information from the primary care sector regarding the circumstances of death was usually too sparse. Again, the clinical pharmacist performed the initial assessment based on the criteria of Naranjo et al. 34 Cases found to be probably drug related and probably preventable were forwarded to the clinical pharmacologist for further evaluation (based on the same criteria).
Sample Size
Assuming that the 180-day risk of drug-related readmission is 20% 9,10,12 and with a bilateral significance level at 5% and 80% power, the necessary number of patients in each group was estimated to be 354 to detect an absolute risk reduction of readmissions of 8%. When the risk of dropouts was taken into account, we decided to include 500 patients in each group.
Randomization and Blinding
The patients were randomly assigned to the usual care, the basic intervention, or the extended intervention group in a 1:1:1 ratio using block randomization (blocks of 6 and 4) with the sequentially numbered, opaque sealed envelope technique. The patients were enrolled consecutively. The randomization was performed at 2 set points. The first randomization was to the usual care group or an intervention group (1:2), with the patient and the pharmacist blinded to which intervention group until the medication review was conducted. After the medication review, the patients in the intervention groups underwent another randomization to the basic intervention or the extended intervention group. The health care professionals from participating departments and from primary care were not informed about the extent of the intervention.
Statistical Analysis
Data were analyzed according to intention to treat. Patients who withdrew their informed consent were followed up until their withdrawal, unless they specifically allowed longer follow-up. Data were analyzed using unadjusted Cox proportional hazards regression for the basic and extended interventions compared with usual care. As censoring events, we included death, withdrawal of consent to follow-up, and planned stop of follow-up after 6 months. Hazard ratios (HRs) were reported with 95% CIs. We used the χ 2 test for dichotomous variables and multinomial logic regression for discrete variables. All P values were considered statistically significant at P < .05. Analyses were performed using Stata software (version 15.1; StataCorp). 
Results
We invited 1873 patients into the study, and 1499 (80.0%) accepted ( Figure 1 ). A total of 503 patients were randomized to usual care; 498, to the basic intervention; and 497, to the extended intervention, with 1 patient excluded owing to incorrect assessment of exclusion criteria. After randomization, 12 were excluded because of an administrative mistake that caused double inclusion, and 19 withdrew their informed consent, prohibiting their inclusion in the primary analysis. Consequently, 1467 patients entered the primary analysis. Baseline characteristics of the included patients are presented in Table 1 . The median age of the patients was 72 years (interquartile range, 63-80 years); 679 (46.3%) were men and 788 (53.7%) were women. All patients from the extended intervention group had a follow-up call. In addition, 262 in this group had a call to their PCP and, if required, their caregiver.
The analysis of the primary outcomes is shown in Table 2 and illustrated in Figure 2 . The extended intervention had a statistically significant effect on the number of patients who experienced a readmission within 30 days after inclusion (HR, 0.62; 95% CI, 0.46-0.84) or within 180 days after inclusion (HR, 0.75; 95% CI, 0.62-0.90) and the number of patients who had a composite of readmissions or ED visits within 180 days after inclusion (HR, 0.77; 95% CI, 0.64-0.93).
We observed a nonsignificant decrease in the number of drug-related readmissions within 30 days (HR, 0.65; 95% CI, 0.39-1.09) or within 180 days (HR, 0.80; 95% CI, 0.59-1.08), drug-related deaths within 180 days (HR, 0.83; 95% CI, 0.22-3.11), and ED visits (HR, 0.74; 95% CI, 0.38-1.44). The basic intervention showed HRs below 1.00 for all end points; however, none of them reached statistical significance ( Table 2 ). The numbers needed to treat were consistently lower for the extended intervention than for the basic intervention except for drug-related death within 180 days. The numbers needed to treat for the main composite end point were 12 for the extended intervention and 65 for the basic intervention. The numbers needed to treat for readmissions within 180 days were 11 for the extended intervention and 65 for the basic intervention; for readmissions with 30 days, 12 for the extended intervention and 41 for the basic intervention (P < .05 for all comparisons).
Subgroup analyses are shown in Table 3 . In brief, the lowest HRs for extensive intervention were seen among men, among the youngest patients, and among those taking 
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the highest number of different drugs. The HR point estimate was below unity (1.00) for all subgroups in the extended intervention. The pharmacists proposed 946 interventions directed to hospital physicians. Of these, 449 (47.5%) involved a risk for drug-related readmission, according to the reference for riskrelated drugs. 24 Seventy-five of 183 interventions directed to primary care (41.0%) concerned such risk-related drugs. The implementation rate of the pharmaceutical interventions suggested during medication review was 61% at the hospital and 66% in primary care, respectively.
Discussion
In this randomized clinical trial, we established that a multifaceted pharmaceutical intervention based on medication review, motivational interview, and postdischarge follow-up for hospitalized patients with polypharmacy can reduce the short-and long-term rates of readmissions. The observed comparable effect on non-drug-related and drug-related readmissions seems counterintuitive. However, we believe that our intervention, if it is effective against, for example, nonadherence, to a large extent could prevent readmissions that are not obviously drug related. If a patient is readmitted because of nonadherence, this will typically manifest itself as a worsening of his or her underlying disease. Unless the patient confesses to being nonadherent, the readmission is unlikely to be recognized as drug related. A meta-analysis 21 from 2016 concluded that medication review does not reduce mortality or hospital readmissions. This conclusion is at odds for several possible reasons, at least with respect to the extended intervention. First, our study is larger than previous studies. The meta-analysis was based on 10 studies with 3575 patients altogether, whereas our study alone included 1499 patients. Second, our study has one of the most intensive interventions in the extensive intervention group. Third, our follow-up is longer than in most other trials. 21, 35, 36 Fourth, our extended intervention was multifaceted, using elements of a motivational interview among other things. The motivational interview technique is nonjudgmental and may more often result in answers that are honest and useful. 27, 28 Single interventions, however intensive, are unlikely to affect, for example, adherence. 20 Finally, with respect to the basic intervention, our results are in agreement with those of the existing literature, essentially showing no clear effect of medication review in itself. 17 
Strengths and Limitations
Among the principal strengths of our study is its fairly large size, thus enabling us to measure the effect in subgroups defined by age, sex, and level of polypharmacy. Another strength is the use of 2 levels of intervention. This allowed us to establish a larger effect with more intensive interventions, which is a strong indicator of a true intervention effect. We had a low level of patients who declined participation (374 [20.0%]), which implies a high degree of generalizability and an intervention that is acceptable for patients. The end points are objective except the drug-related hospital contacts and deaths, for which the relation to drug use entails an element of subjectivity. The acceptance rate for the proposed changes was 61% in secondary care and 66% in primary care, thus indicating a high level of acceptability compared with similar studies. 13 Some potential weaknesses and limitations need to be considered. The study could not be entirely blinded because, for Abbreviations: ED, emergency department; HR, hazard ratio.
a Indicates readmission or ED visit within 180 days of inclusion.
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example, the intervening pharmacist and the patient would know the result of the allocation. We used a blinded randomization procedure 37,38 and also blinded those who ascertained drugrelated admissions. In addition, the pharmacist who performed the medication review was unaware of whether the patient would be assigned to the basic or the extensive intervention, thereby avoiding different levels of diligence being put into the medication review. Another potential problem is that of intervention carryover between assignment groups. 39 Some of the staff at participating wards could have learned elements of the intervention and applied it to some of the patients in the usual care group. This would have the effect of diminishing the contrast between the usual care and intervention groups, thereby underestimating the true effect of our intervention. We had more dropouts in the extensive intervention group than in the usual care or the basic intervention group. Our patients had a high burden of morbidity, and some in the extensive intervention group were frustrated by the additional health care contacts and withdrew their informed consent. A similar problem has been reported by others.
40
To account for this, we have analyzed the data based on intention to treat; unfortunately, 18 patients in the extensive intervention group also withdrew their consent for us to follow up based on intention to treat. Because the proportion is low (3.6%), we believe this to be of minor significance. Another limitation is that, because of the requirements for informed consent, patients with severe dementia and delirium were underrepresented in our study population. Dementia is prevalent among the patients in our age group, 41 and how well our intervention would work with a cognitively impaired population is unknown.
Conclusions
This study shows that hospital pharmacists may play an important role in preventing hospital readmissions. 
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Background
In the literature, the transition between the primary and secondary healthcare sectors is described as being a sensitive area regarding patient medication. (1), (2), (3) . Especially the transition from hospital to primary healthcare can be associated with mistakes, which occur during and after discharge and are caused by changes to the patient's medical treatment during admission. (4), (5) . The more drugs the patient takes, the larger the risk of drug related problems. (6) The consequences for the patient can be undertreatment, overtreatment, mistakes in medication, more numerous and also more serious side effects than assumed, low compliance or in worst case readmissions (2), (7) . In order to achieve a continuous and safe drug handling in the transition between the healthcare sectors good communication is required and this is presently described as been insufficient. (1), (2) . Description of the patients' current medication with later changes and reason for changes in the patient's medication during admission is often incomplete in the discharge summary (8), (9) . This makes it difficult for the next doctor, taking over the care of the patient to keep an overview of the current medical treatment. In Sweden a discharge summary which includes a medication report has been developed, which all patients and the next doctor receive at discharge. This has reduced the number of medication errors (10), (11), drug related clinical risks and administrative corrections (12) at transitions between healthcare sectors. Empirical studies have shown that 11 to 20 % of hospital admissions are drug related (13), (14), (15) . In an evidence report from 2006 on drug related problems it is estimated based on foreign studies, that 69.000 -162.000 annual hospital admissions are drug related in Denmark (16) . It has been unclear, whether a medication review done by a clinical pharmacist has any effect on the number of admissions. A meta-analysis from 2007 including 32 foreign studies concluded that medication review done by a clinical pharmacist did not make a significant difference to the number of admissions (17) . Newer studies however show increasing evidence that medication review reduces the number of drug related admissions and other drug related problems (15), (18) resulting in financial savings (18), (19), (20), (21) . In addition follow-up calls to the patients within one week of discharge have resulted in a reduction of the number of side effects, A&E visits, and admissions (22), (23) . At time of transition from hospital to primary healthcare it is important to contact to the GP and the primary pharmacy to ensure that any changes to the patient's medication, made during admission are implemented in the primary healthcare setting (24) . This contact is especially important with regard to patients who receive dose dispensed drugs, as dose dispensing also is associated with risks of medication errors at times of transition (3), (25) . A study has shown that the number of these errors can be reduced by support from a clinical pharmacist at time of discharge (25) . A patient is classified as non-compliant, if less than 80 % of the prescribed drug doses have been taken as prescribed. (26), (27) . It is estimated that approximately 50 % of patients with chronic illnesses do not take their medication as prescribed, which potentially has negative consequences for both the patient and the health care system, in worst case to increased morbidity and mortality (22), (27) . Thus, it is important to uncover which patients are non-compliant and need to change their behaviour. The patient dialogue prior to discharge has led to a reduction of discrepancies in the medical treatment, and had a positive effect on compliance (22), (28) . Motivational interviewing in health care is an evidence based, communication tool to increase compliance by mobilising the patient's motivation to change lifestyle (30) .
In the literature a number of interventions are described which have been tested to create a safer course during transition between healthcare sectors, i.e. the course, when patients are admitted to hospital and discharged to the general practitioner (24), (31), (32), (33) . In spite of this, it has not yet been defined, precisely which intervention(s) secure an efficient communication and knowledge sharing between the primary and secondary healthcare sectors, and thus ensuring a continuous course of medication for the patient.
Clinical pharmacists are presently conducting medication reviews in several Acute Assessment Units (FAM) in Denmark (34) . This study will test an approach including medication review, medication discharge dialogue and a follow up telephone call to the patient as well as contact to the primary healthcare sector, the general practitioner and pharmacy respectively in order to improve the continuity of the medical treatment.
The clinical pharmacist will take an active part in securing rational pharmacotherapy, increased compliance, and patient safety at time of discharge from the hospital to the GP.
Aim
The aim of the study is to investigate the effect of medication review, medication discharge dialogue and follow up calls to the patient, general practitioner and the pharmacy on readmissions and patient compliance at discharge from hospital to general practice. The study will test whether the above combination of pharmaceutical interventions can reduce the number of readmissions and/or time to next admission will be prolonged. The hypothesis, that non-compliant patients are readmitted more often the compliant patients will be tested. The combination of pharmaceutical interventions will be compared to an intervention, including only a focused medication review compared to a control group.
Method
Design
A prospective, blinded, randomised controlled multi-centre study on patients admitted to the Acute Assessment Unit (FAM) 
Exclusion criteria
  The patient has participated in one or more similar intervention studies.   The patient is declared terminally ill.   The patient is poisoned with suicidal intent   The patient requires constant supervision/is suicidal   The patient has impressive and/or expressive aphasia   The patient has severe dementia   The patient is detained   The patient is isolated
Information and collaboration between primary and secondary healthcare sector
Written information for patients and information material for doctors and nurses at the hospital is provided prior to starting the study. Corresponding information material is provided for doctors and pharmacies in the primary care sector. Information material for all primary pharmacies in Denmark is distributed via the Association of Danish Pharmacies and information material is provided for general practitioners through regional newsletters.
Patient selection, randomization and data collection.
Based on a power calculation it is decided to include 1500 patients in the study. The patients are randomized into one of three groups: basic intervention group, advanced intervention group, and control group. 500 patients are included into each group. The patients are randomized first to the intervention group or the control group respectively. Everyone in the intervention group undergoes a medication review, after which the patients in the intervention group are re-randomized. To minimize the risk of bias both the clinical pharmacist and the patient are blinded as to whether the patient belongs to the basic intervention group or the advanced intervention group, until the medication review is completed. The civil registration numbers of all the patients, who have been included in or have rejected the study, are registered. At each new admission the register will be checked to see if the patient is registered, so that the same patient is included only once. The patient flow is illustrated in the diagram in figure 1 . 
Patient groups
Patients in all three groups are examined for compliance, where compliance is defined as an expression of the level of concordance between the patient's actual drug intake and the treatment chosen by the doctor.
Patients are classified as non-compliant if prescriptions for less than 80% of the prescribed doses are redeemed.
Control group
The purpose of the control group is to have the same starting point for all three groups, providing a base for comparison of data between the groups. These patients do not receive a medication review, discharge dialogue and follow up from a clinical pharmacist.
Basic intervention group
A clinical pharmacist does a medication review once during the admission. As a minimum the admission notes are required to be completed and available. Any intervention proposals are noted in the patient's electronic patient records, EPJ. The medication review is done systematically from a defined guideline. Any intervention proposals are entered into the electronic database. The clinical pharmacist does a medication review with the medical records as a primary source but also interviews the patient and uses the Shared Medical Card (FMK) if further information is necessary for clarification.
Advanced intervention group
The patients undergo a medication review as described for the basic intervention group, where the same registrations are made. Once a doctor from FAM has adjusted the medication upon discharge 7 , possibly with the assistance of a clinical pharmacist, the clinical pharmacist delivers an actual medication list and holds a medication discharge dialogue, including a motivational interview. If the patient is transferred to a different medical ward during the admission, the motivational interview can be held before the transfer to a different ward. After the patient is discharged the clinical pharmacist sends a list of suggested interventions, which have not been decided upon during admission, to the patient's GP. The patient is contacted 3-5 days after discharge in order to follow up on the discharge dialogue. The home care services, GP and primary pharmacy are contacted by telephone also within 3-5 days of discharge as required.
Figure 2. Intervention overview.
The clinical pharmaceutical interventions shown in figure 2 are done by selected clinical pharmacists from Hospital Pharmacy of Funen, Hospital Pharmacy of Region Zealand and The Regional Hospital Pharmacy, Viborg. The clinical pharmacists are trained prior to study start in order to minimise the risk of cultural differences and variations in work procedures between the regions influencing the data. 
Outcome measures
Data analysis
Data are analysed both for all hospitals in total and for each hospital separately, in order to identify any local differences. Furthermore, data are analysed from the information continuously being registered in patient protocols.
Drug related admissions and readmissions.
Each hospital administration are able to access data for all admissions regarding number of inpatient days, number of A&E visits, number of readmissions, and mortality. An impartial clinical pharmacologist is manually reviewing patient records to estimate the share of drug related admissions, readmissions, and drug related deaths out of all readmissions and deaths. The inventory of unscheduled visits to the GP is based on The National Health Insurance Service Register administrated by the National Board of Health, which again is based on reimbursement codes. In case of doubt the respective medical practices are contacted to ascertain whether the visit was scheduled.
As it is important to know the range of the interventions made during the admission, the effect of the primary sector's acceptance rate of interventions made by the secondary sector is evaluated. The Shared Medical Card (FMK) is used for this purpose and the GP is also contacted. Thus it can be measured whether there will be a knock-on effect from the secondary to the primary sector. The acceptance rate during the admission is calculated using an extract of data from the Excel sheet where interventions and suggestions are registered.
Compliance
After six months calculation as to whether the patient is compliant or non-compliant is made based on the assumption that a patient is non-compliant if prescriptions are redeemed for less than 80% of the prescribed doses. This calculation is based on the Shared Medical Card (FMK).
Statistical analysis
Drug related admissions and readmissions
Time until new contact to the health service, death, number of admissions and readmissions are analysed using survival statistics (Kaplan-Meier graphs and Cox-regression). Likewise, the persistence of completed and accepted interventions after discharge are described by survival statistics, i.e. as an analysis of waiting time until the patient receives the medication in use prior to the intervention
Compliance
The survival statistics, as described above, are used for analysis of non-persistence as a measure of noncompliance, as the patient is assumed to be persistent at discharge but may become non-persistent at a variable time point after discharge.
Another measure of compliance is the proportion of days covered, which describes a ratio between dispensed drug quantity within a given period and the drug quantity, having been dispensed in case of perfect compliance. Parametrical analyses are used in analyses of this measure.
Power calculation
Based on an estimated risk of readmission at 20 % in the control group, a two-sided level of significance at 5%, and 80% power, the study will require 354 patients in each intervention group and in the control group in order to show a reduction in the prevalence of admissions to 12 %. Thus, 1062 patients will be needed in total. In order to account for possible withdrawals it is decided to include 500 patients in each group, 1500 patients in total. In cases of withdrawal the patient is included until the time of withdrawal, corresponding to a per protocol analyses.
Ethics
The Danish Data Protection Agency and the Regional Ethics Committee have both been notified of the study. The Heads of Departments have given permission to access the department's electronic records system. Written informed consent is required, whereby the patients accept that we gain access to the electronic records and Shared Medical Card (FMK), contact patient's general practitioner and authorise that we deactivate and thus invalidate outdated prescriptions at the primary pharmacy, which according to the National Health-IT is in accordance with current legislation. Identifiable personal data will be anonymised when registered/published.
